This program is supported by an independent educational grant from Lilly.
Join Dr. Douglas Kirsch for this CME-accredited podcast as he explores how clinicians can move beyond simply prescribing PAP to achieving effective, sustainable control of obstructive sleep apnea (OSA).
Using a real-world patient case, this episode examines practical approaches to troubleshooting PAP, integrating weight and cardiometabolic management, considering emerging treatment options, and coordinating long-term care. Listeners will gain practical strategies for developing a multimodal, patient-centered approach to OSA management.
This is episode two of three, find episodes one and three here.
Who Should Listen?
Primary care physicians and sleep specialists involved in the care of patients with OSA.
This podcast has four segments:
- Optimizing PAP Therapy – Look beyond the prescription to identify and troubleshoot the barriers preventing effective PAP treatment.
- Building a Multimodal OSA Plan – Explore why effective OSA care needs to address obesity, cardiometabolic risk, and patient priorities alongside PAP.
- Exploring Emerging Treatment Options – Consider where anti-obesity pharmacotherapy may fit within an individualized OSA treatment plan.
- Coordinating Long-Term Care – Discover how shared goals, coordinated follow-up, and multidisciplinary care can turn separate treatments into one integrated plan.
Faculty
Dr Douglas Kirsch is Medical Director of Sleep Medicine at Atrium Health and a Professor of Internal Medicine and Neurology. A board-certified sleep medicine specialist, he has extensive expertise in the diagnosis and management of sleep disorders, with a particular research focus on obstructive sleep apnea. His research examines the impact of OSA treatment on patient hospitalizations and explores the use of consumer wearable devices to assess sleep in the home setting. Dr Kirsch is a former President of the American Academy of Sleep Medicine and is dedicated to improving sleep health and patient well-being.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Douglas Kirsch, faculty for this educational activity, has the following relevant financial relationships: Scientific Advisory Board Apnimed, Incannex, Huxley Medical. Expert Panel Carelon. Consulting ResMed.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Continuing Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting October 6th 2026, and will expire on July 1st 2028.